Literature DB >> 11469288

Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases.

C Mehler1, C Wewetzer, U Schulze, A Warnke, F Theisen, R W Dittmann.   

Abstract

Psychopathology in severely anorexic patients often seems to be of compulsive and delusional quality rendering therapeutic approaches extremely difficult. With conventional therapeutic regimes failing, administration of the novel antipsychotic olanzapine induced remarkable improvement in five cases reported here. Paranoid ideation concerning body image or weight gain decreased and sedative effects helped to reduce inner tensions and phobia with respect to food intake. Olanzapine, therefore, might represent an important therapeutic tool in anorexic patients who present the following characteristics: long-term history of anorexia nervosa mostly with several hospitalisations, missing perception of their severe state of illness, refusal of therapy, delusional quality of anorexic thinking, risk of discontinuation of therapy with life-threatening consequences.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11469288     DOI: 10.1007/s007870170039

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  17 in total

1.  Challenges in conducting a multi-site randomized clinical trial comparing treatments for adolescent anorexia nervosa.

Authors:  James Lock; Harry Brandt; Blake Woodside; Stewart Agras; W Katherine Halmi; Craig Johnson; Walter Kaye; Denise Wilfley
Journal:  Int J Eat Disord       Date:  2011-04-14       Impact factor: 4.861

2.  Challenges associated with controlled psychopharmacological research trials in adolescents with eating disorders.

Authors:  Mark L Norris; Wendy Spettigue; Annick Buchholz; Katherine A Henderson
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2007-11

3.  Olanzapine use in adolescent anorexia nervosa.

Authors:  K Dennis; D Le Grange; J Bremer
Journal:  Eat Weight Disord       Date:  2006-06       Impact factor: 4.652

Review 4.  The safety of olanzapine in young children: a systematic review and meta-analysis.

Authors:  Jacqueline Flank; Lillian Sung; Christopher C Dvorak; Wendy Spettigue; L Lee Dupuis
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

5.  Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.

Authors:  Vikas Duvvuri; Taya Cromley; Megan Klabunde; Kerri Boutelle; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2011-02-22       Impact factor: 4.861

6.  Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders.

Authors:  S Gebhardt; M Haberhausen; J-C Krieg; H Remschmidt; M Heinzel-Gutenbrunner; J Hebebrand; F M Theisen
Journal:  J Neural Transm (Vienna)       Date:  2007-03-20       Impact factor: 3.575

Review 7.  The psychopharmacotherapy of anorexia nervosa: clinical, neuroendocrine and metabolic aspects.

Authors:  G Abbate Daga; L Gianotti; V Mondelli; R Quartesan; S Fassino
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

8.  A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study.

Authors:  Jennifer Hagman; Jane Gralla; Eric Sigel; Swan Ellert; Mindy Dodge; Rick Gardner; Teri O'Lonergan; Guido Frank; Marianne Z Wamboldt
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-08-05       Impact factor: 8.829

Review 9.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder.

Authors:  Nicholas T Bello; Bryn L Yeomans
Journal:  Expert Opin Drug Saf       Date:  2017-10-31       Impact factor: 4.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.